Open AccessAbacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial
Author(s) -
Allison Martin,
Janaki Amin,
David A. Cooper,
Andrew Carr,
Anthony D. Kelleher,
Mark Bloch,
David Baker,
Ian Woolley,
Sean Emery
Publication year - 2010
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32833f147f
Subject(s) - abacavir , emtricitabine , medicine , lamivudine , lopinavir , serum amyloid a , immunology , gastroenterology , viral load , inflammation , human immunodeficiency virus (hiv) , hepatitis b virus , virus , antiretroviral therapy
The Simplification of antiretroviral therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine trial (STEAL) study randomized HIV participants to switch existing nucleoside reverse transcriptase inhibitors (NRTI) to either abacavir/lamivudine (ABC/3TC; n = 179) or tenofovir/emtricitabine (TDF/FTC; n = 178). An increased risk in cardiovascular disease (CVD) was reported (hazard ratio 7.7, P = 0.048) in ABC/3TC recipients compared with TDF/FTC in the STEAL study. The impact of ABC/3TC treatment on a range of CVD and inflammatory biomarkers was explored.